Camena Bioscience
Camena Bioscience develops a nucleic acid synthesis technology platform called gSynth that delivers high-fidelity, transfection-ready DNA three times faster than traditional methods. The platform addresses bottlenecks in the design-build-test-learn (DBTL) cycle by enabling sequence-perfect DNA synthesis regardless of structural complexity, supporting applications in personalized mRNA vaccines, cell and gene…
Funding snapshot
About
Camena Bioscience develops a nucleic acid synthesis technology platform called gSynth that delivers high-fidelity, transfection-ready DNA three times faster than traditional methods. The platform addresses bottlenecks in the design-build-test-learn (DBTL) cycle by enabling sequence-perfect DNA synthesis regardless of structural complexity, supporting applications in personalized mRNA vaccines, cell and gene therapies, and CRISPR screening. gSynth can synthesize long, complex, and highly repetitive sequences including GC-rich promoters, enhancers, terminators, and Cas12a constructs that are difficult to manufacture with traditional chemical synthesis. The company serves drug discovery labs and has recently appointed Gregory P. McGuinness as CEO to lead commercialization of the gSynth platform for AI-driven antibody discovery. Founded in 2016 and headquartered in Cambridge, United Kingdom, Camena Bioscience has raised approximately $10 million in Series A funding from investor Mercia.
Business model
Genomics > Applied Genomics > Synthetic Biology,
Life Sciences Platforms and Tools > Instruments > Genomics > Nucleic Acid Synthesis
Team background
College Wise > University College London
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.